AstraZeneca’s (AZN) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft restated their hold rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. They currently have a £117 price target on the biopharmaceutical company’s stock.

Several other analysts have also recently weighed in on AZN. Jefferies Financial Group reissued a “buy” rating and set a £175 price objective on shares of AstraZeneca in a report on Wednesday, September 9th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a £145 target price on shares of AstraZeneca in a research note on Tuesday, September 8th. Citigroup lifted their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Berenberg Bank dropped their price target on shares of AstraZeneca from £160 to £150 and set a “buy” rating for the company in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of £150.

AstraZeneca Trading Up 2.4%

Shares of AZN opened at £124.28 on Tuesday. The stock’s fifty day simple moving average is £121.79 and its 200-day simple moving average is £134.47. The firm has a market capitalization of £192.75 billion, a PE ratio of 18.60, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. AstraZeneca has a 12-month low of £107.84 and a 12-month high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10.

Insider Activity

In related news, insider Michel Demare acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is owned by corporate insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.